MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/art.34661

Медицинская библиотека · Arthritis and rheumatism · 2012

Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis.

Bennett Tellen D, Fluchel Mark, Hersh Aimee O, Hayward Kristen N, Hersh Adam L, Brogan Thomas V, Srivastava Rajendu, Stone Bryan L, Korgenski E Kent, Mundorff Michael B, Casper T Charles, Bratton Susan L

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

OBJECTIVE

To describe patient demographics, interventions, and outcomes in hospitalized children with macrophage activation syndrome (MAS) complicating systemic lupus erythematosus (SLE) or juvenile idiopathic arthritis (JIA).

METHODS

We performed a retrospective cohort study using data recorded in the Pediatric Health Information System (PHIS) database from October 1, 2006 to September 30, 2010. Participants had International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for MAS and either SLE or JIA. The primary outcome was hospital mortality (for the index admission). Secondary outcomes included intensive care unit (ICU) admission, critical care interventions, and medication use.

RESULTS

A total of 121 children at 28 children's hospitals met the inclusion criteria, including 19 children with SLE and 102 children with JIA. The index admission mortality rate was 7% (8 of 121 patients). ICU admission (33%), mechanical ventilation (26%), and inotrope/vasopressor therapy (26%) were common. Compared to children with JIA, those with SLE had a similar mortality rate (6% versus 11%, respectively; exact P = 0.6). More patients with SLE than those with JIA received ICU care (63% versus 27%; P = 0.002), received mechanical ventilation (53% versus 21%; P = 0.003), and had cardiovascular dysfunction (47% versus 23% received inotrope/vasopressor therapy; P = 0.02). Children with SLE and those with JIA received cyclosporine at similar rates, but more children with SLE received cyclophosphamide and mycophenolate mofetil, and more children with JIA received interleukin-1 antagonists.

CONCLUSION

Organ system dysfunction is common in children with rheumatic diseases complicated by MAS, and more organ system support is required in children with underlying SLE than in children with JIA. Current treatment of pediatric MAS varies based on the underlying rheumatic disease.

Для цитирования: Bennett Tellen D, Fluchel Mark, Hersh Aimee O, Hayward Kristen N, Hersh Adam L, Brogan Thomas V, Srivastava Rajendu, Stone Bryan L, Korgenski E Kent, Mundorff Michael B, Casper T Charles, Bratton Susan L. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis.. Arthritis and rheumatism. 2012. DOI: 10.1002/art.34661.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.